FDA 483 OBSERVATION · #126 OF 1,945 MOST-CITED

Validation lacking for sterile drug products

FDA cited this observation 243 times across 210 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs243
BY FISCAL YEAR
FY202624
FY202526
FY202430
FY202317
FY202226
FY202110
FY20209
FY201932
FY201813
FY201722
FY201634

What this observation means, and how to comply

SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.

21 CFR 211.113(b)

Written procedures to prevent microbiological contamination of drug products purporting to be sterile are lacking or inadequate — including validation of the sterilization process, aseptic processing, and any sterility-assurance controls required by §211.113(b).

Why FDA writes it — For a sterile product, sterility cannot be tested into the batch — it must be assured by a validated process. FDA protects against releasing supposedly-sterile drugs on the strength of an unvalidated or poorly validated process, where a contaminated unit reaching a patient can be fatal.

HOW TO COMPLY
  • Validate the sterilization or aseptic process with documented protocols, worst-case challenges, and defined acceptance criteria.
  • Maintain media fills, environmental monitoring, and sterility-assurance controls with justified alert and action limits.
  • Revalidate on significant changes to process, equipment, load, or facility, and on adverse trend signals.
  • Have the quality unit review validation data and monitoring results before releasing any sterile batch.
WHY FIRMS GET CITED
  • Aseptic process qualification relies on a one-time study never revalidated after line or load changes.
  • Environmental and media-fill excursions are handled as isolated events rather than as validation-state signals.
PROFESSIONAL · REMEDIATION PLAYBOOK · SPEQ SYNTHESIS

How to close this finding — and stop it recurring

CHECKING ACCESS

Checking your access…

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 6.5× the rate of the average FDA-cited firm (50.5% vs 7.8%), across 210 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Steril-Gene Life Sciences Private Ltd · Puducherry · Drugs · 2026-08-12

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Galentic Pharma (India) Pvt. Ltd · Gandhidham · Drugs · 2026-08-11

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Hetero Labs Ltd. Unit VI · Mahaboob Nagar · Drugs · 2026-06-26

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Scinopharm Taiwan, Ltd. · Tainan City · Drugs · 2026-06-23

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Oakwood Laboratories LLC · Solon, Ohio · Drugs · 2026-05-21

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Samchundang Pharm Co., Ltd. · Hwaseong · Drugs · 2026-05-19

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Contamination control →Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →